MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial. - Pearson AT; Muzaffar J; Kirtane K; Bellile E; Suresh K; Rosenberg AJ; Worden F; Chung CH; Vokes E; Brenner JC; Bhangale A; McHugh J; et al. (Nature communications, 2026)